Investigative Ophthalmology & Visual Science Cover Image for Volume 62, Issue 8
June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Characteristics of patients receiving intravitreal injections during COVID-19
Author Affiliations & Notes
  • Christian Fritz Hyacinthe
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Saena Arifeen Sadiq
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Andrew Clingerman
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Ria Desai
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Alice T Lyon
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Rukhsana Mirza
    Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Christian Hyacinthe, None; Saena Sadiq, None; Andrew Clingerman, None; Ria Desai, None; Alice Lyon, None; Rukhsana Mirza, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1992. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christian Fritz Hyacinthe, Saena Arifeen Sadiq, Andrew Clingerman, Ria Desai, Alice T Lyon, Rukhsana Mirza; Characteristics of patients receiving intravitreal injections during COVID-19. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1992.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : After the Illinois shelter-in-place COVID-19 mandate was instituted on March 16, 2020, outpatient ophthalmology care was limited to patients with vision-threatening conditions. In order to better understand the impact of the mandate on patients receiving intravitreal injections (IVIs), we compared key demographic and clinical features of patients seen before and after quarantine measures.

Methods : Retina patients receiving IVIs at Northwestern Medicine sites between 12/1/19 and 6/30/20 were identified and divided into “pre-COVID” (PC) and “Strict-Quarantine” (SQ) groups (12/1/19-3/15/20 and 3/16/20-6/30/20, respectively). A subset of patients lost to follow-up (LTFU), defined as having been seen at least once in the PC period but not at all during the SQ period, were also identified. Comparison of primary diagnoses and self-reported demographic data was performed between these three sub-groups. Primary diagnoses necessitating IVIs were identified as age-related macular degeneration (AMD), diabetic retinopathy (DR), retinal vein occlusion (RVO), and other causes of neovascularization (other).

Results : 1426 injections were administered to 716 patients during the PC period compared to 1121 injections to 637 patients during the SQ period. More injections per patient were performed in the PC period compared to the SQ period (1.99 ± 1.00 vs 1.76 ± 0.87, p = 5.87E-06). There were no significant differences in primary diagnosis or demographic characteristics between these two groups (p = 0.852, 0.974, respectively). 24.2% of PC patients (173 patients) were identified as LTFU. Of the LTFU patients, a lower percentage identified as White and higher percentages identified as Black, Asian and Other in comparison to the PC (p = 0.0413) and SQ (p = 0.00853) groups. LFTU patients proportionally had a higher percentage of DR (35.88%) and RVO (20.59%) primary diagnoses and a lower proportion of AMD (33.53%) primary diagnoses than patients in the PC (p=0.0011) and SQ (p=0.0014) groups.

Conclusions : The COVID-19 pandemic resulted in disruption of normal ophthalmic clinic operations. Because Black and other non-white patients and patients with diabetic retinopathy made up higher percentages of the LTFU group, efforts should be made to understand and address any barriers to medically necessary follow-up during this unprecedented public health crisis.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×